NovaTech Biomedical seeks $12 million in Series A funding. The VC expects an exit in Year 6 with projected revenue of $60 million at a 3.5x revenue multiple, and requires a 55% annual return. NovaTech currently has 4 million shares outstanding. The pre-money valuation is closest to: